CLINICAL CANCER RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2020-10-01 zkk1760

请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？

266 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2021-09-17 rayhuang_1003

估计要凉了，这么快的就进入了pending阶段，肯定拒稿
Stage Start Date
Decision Pending 2021-09-16 16:31:01
Under Review 2021-09-16 07:29:50
Under Editorial Consideration 2021-09-15 23:01:37
Initial QC 2021-09-14 13:24:49
Manuscript Submission 2021-09-14 11:33:22

293 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2023-10-19 ms8000001750053996 来自广东省

Stage Start Date
Under Editorial Consideration 2023-10-18 12:49:26
Under Review 2023-10-18 05:25:13
Under Editorial Consideration 2023-10-17 09:02:03
Initial QC 2023-10-14 12:04:38
Manuscript Submission 2023-10-08 10:02:56
为什么我有2个编辑审核呢

45 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2021-01-31 祝福中国

刚投了一篇……

157 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2024-03-16 ms9000001180012589 来自上海

Stage Start Date
Under Editorial Consideration 2024/3/12
Under Review 2024/3/11
Under Editorial Consideration 2024/3/11
Initial QC 2024/3/7
Manuscript Submission 2024/3/5

18 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2023-10-03 liuluofei 来自广东省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：非小细胞肺癌
经验分享：Stage Start Date
Under Editorial Consideration 2023-10-02 09:57:28
Under Review 2023-09-21 06:40:54
Under Editorial Consideration 2023-09-20 08:48:21
Initial QC 2023-09-18 13:01:13
Manuscript Submission 2023-09-18 10:44:07

61 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2024-02-06 ms7000000158522052 来自北京

Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06

30 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2021-07-15 幸运加满

偏重的研究方向：肿瘤
经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。

138 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2023-01-12 ms8000001761301688 来自河南省

偏重的研究方向：肿瘤;临床
经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19

77 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=889601, encodeId=c272889601cd, content=请问一下在编辑手上呆了7分分钟就under review，是送外审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210523/c8321283db614d0693d5a01b210d9802/ad54b342b6244724a259d2d8f8c12abe.jpg, createdBy=0d165353621, createdName=zkk1760, createdTime=Thu Oct 01 18:25:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052283, encodeId=55cf1052283fc, content=估计要凉了，这么快的就进入了pending阶段，肯定拒稿 Stage Start Date Decision Pending 2021-09-16 16:31:01 Under Review 2021-09-16 07:29:50 Under Editorial Consideration 2021-09-15 23:01:37 Initial QC 2021-09-14 13:24:49 Manuscript Submission 2021-09-14 11:33:22, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06ca5577390, createdName=rayhuang_1003, createdTime=Fri Sep 17 10:55:26 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date Under Editorial Consideration 2023-10-18 12:49:26 Under Review 2023-10-18 05:25:13 Under Editorial Consideration 2023-10-17 09:02:03 Initial QC 2023-10-14 12:04:38 Manuscript Submission 2023-10-08 10:02:56 为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=921678, encodeId=f2a89216e889, content=刚投了一篇……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=祝福中国, createdTime=Sun Jan 31 13:36:22 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date Under Editorial Consideration 2024/3/12 Under Review 2024/3/11 Under Editorial Consideration 2024/3/11 Initial QC 2024/3/7 Manuscript Submission 2024/3/5 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：非小细胞肺癌 经验分享：Stage Start Date Under Editorial Consideration 2023-10-02 09:57:28 Under Review 2023-09-21 06:40:54 Under Editorial Consideration 2023-09-20 08:48:21 Initial QC 2023-09-18 13:01:13 Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向：肿瘤 经验分享：请问大家怎么确定这个杂志是真外审还是假外审啊～感觉投稿都会有under review这个阶段，但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109936, encodeId=aa12210993622, content=偏重的研究方向：肿瘤;临床 经验分享：同志们，见过这种吗？他这个under rev咋这么快，这应该是没送外审吧？ Under Review 2023-01-10 11:25:52 Under Editorial Consideration 2023-01-10 11:05:59 Initial QC 2023-01-08 08:14:19 Manuscript Submission 2023-01-08 04:16:19 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc968298560, createdName=ms8000001761301688, createdTime=Thu Jan 12 10:54:49 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1189131, encodeId=924c1189131a0, content=请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ec85701429, createdName=灵动梦幻, createdTime=Sat Jan 29 19:13:15 CST 2022, time=2022-01-29, status=1, ipAttribution=)]

2022-01-29 灵动梦幻

请问各位科研大佬，Waiting for Potential Reviewer Assignment是指已经到了送审状态吗？麻烦请教下，谢谢

265 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务